share_log

4D pharma (LON:DDDD) Shares Up 5%

4D pharma (LON:DDDD) Shares Up 5%

4D Pharma(LON:DDDD)股价上涨5%
Financial News Live ·  2022/08/03 11:21

Shares of 4D pharma plc (LON:DDDD – Get Rating) shot up 5% on Monday . The company traded as high as GBX 16.86 ($0.21) and last traded at GBX 16.66 ($0.20). 912,370 shares were traded during mid-day trading, a decline of 69% from the average session volume of 2,957,490 shares. The stock had previously closed at GBX 15.86 ($0.19).

周一,4D制药公司(LON:DDDD-GET Rating)的股价飙升5%。该公司股价一度高达16.86英镑(合0.21美元),最新报16.66英镑(合0.20美元)。午盘成交量为912,370股,较2,957,490股的平均成交量下降69%。该股此前收盘报15.86英镑(合0.19美元)。

4D pharma Stock Performance

4D医药股表现

The company has a debt-to-equity ratio of 39.50, a quick ratio of 4.72 and a current ratio of 5.21. The stock has a market cap of £30.04 million and a price-to-earnings ratio of -1.08. The stock has a fifty day simple moving average of GBX 21.66 and a two-hundred day simple moving average of GBX 32.26.

该公司的债务权益比率为39.50,速动比率为4.72,流动比率为5.21。该股市值为3004万GB,市盈率为-1.08倍。该股的50日简单移动均线为21.66英镑,200日简单移动均线为32.26英镑。

4D pharma Company Profile

4D制药公司简介

(Get Rating)

(获取评级)

4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease.

4D制药公司及其子公司在英国开发活的生物治疗产品(LBPS)。该公司开发治疗候选药物,包括用于治疗癌症和免疫肿瘤学疾病的MRx0518;用于治疗哮喘的MRx-4DP0004;用于治疗中枢神经系统疾病的MRx0029和MRx0005;用于肠易激综合征的Blautix;以及用于儿童克罗恩病的Thetanix。

Recommended Stories

推荐故事

  • AutoNation Stock is Firing on All Pistons
  • Caterpillar Falls To Strong Support Near Bottom Of Range
  • AMD Q2 Earnings Beat Expectations Significantly, Is AMD A Buy?
  • 3 Health Care Stocks in Great Financial Health
  • Amazon Names Itself A Top Stock Of Q3 Contender
  • AutoNation股票正在向所有活塞开火
  • 卡特彼勒跌至接近区间底部的强劲支撑
  • AMD第二季度收益显著超出预期,AMD A买入吗?
  • 大财务健康中的3只医疗保健类股
  • 亚马逊称自己是第三季度竞争者的首选股票

Receive News & Ratings for 4D pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D pharma and related companies with MarketBeat.com's FREE daily email newsletter.

接受4D药房日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对4D制药及相关公司评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发